Will the FDA approve a cure for Type 1 diabetes before 2033?
Yes refers to: Before 2033
Short Answer
Both the model and the market expect the FDA to approve a cure for Type 1 diabetes before 2033, with no compelling evidence of mispricing.
1. Market Behavior & Drivers
This market exhibits a sideways trading pattern, with the probability of an FDA approval for a Type 1 diabetes cure before 2033 oscillating within a narrow 8-point range. The price has established clear support at 32.0% and resistance at 40.0%. The most significant price action occurred recently with a sharp 8.0 percentage point spike to 40.0% on April 24, 2026, which was immediately and fully reversed by an 8.0 percentage point drop back to 32.0% the following day. Given the lack of provided news or external developments, these movements do not appear to be driven by new fundamental information and may reflect specific trading activity or a short-lived shift in sentiment within the market itself.
The total trading volume of 343 contracts across 161 data points is relatively low, suggesting a market with limited participation. This low liquidity could explain the sharp price swings, as a small number of trades can have an outsized impact on the price. The immediate reversal of the April 24th spike indicates that the move to the 40.0% resistance level was not sustained and lacked broad market conviction, with traders quickly pushing the price back down to the established support level at 32.0%.
Overall, the chart suggests that market sentiment is stable but uncertain, holding the probability at roughly one-in-three. The defined trading range between 32.0% and 40.0% indicates that traders have yet to see a catalyst strong enough to break out of this equilibrium. The market appears to be in a holding pattern, awaiting significant clinical trial data or regulatory news that could fundamentally alter the long-term outlook for a cure. The current price of 32.0% rests at the bottom of this range, reflecting a cautious baseline sentiment.
- Vertex's VX-880 shows significant insulin independence and sustained efficacy in trials.
- Multiple advanced technologies are reversing Type 1 diabetes in clinical trials.
- FDA has not formally established Type 1 diabetes functional cure endpoints.
- Islet and VX-880 transplantations present manageable immunosuppression risks.
- Vertex's VX-880, an advanced therapy, completed enrollment in studies.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Before 2033 | 32.0% | 35.6% | Overcoming scientific and regulatory challenges is key for a Type 1 diabetes cure's FDA approval. |
2. Price Chart
Historical Price (Probability)
Outcome probability
Date
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📉 April 25, 2026: 8.0pp drop
Price decreased from 40.0% to 32.0%
Outcome: Before 2033
What happened: No supporting research available for this anomaly.
📈 April 24, 2026: 8.0pp spike
Price increased from 32.0% to 40.0%
Outcome: Before 2033
What happened: No supporting research available for this anomaly.
4. Market Data
Contract Snapshot
The market resolves to "Yes" if the U.S. FDA approves a Type 1 diabetes cure before January 1, 2033, defined as an FDA-approved product that eliminates ongoing exogenous insulin therapy and restores normal endogenous insulin production without other continuous therapeutic interventions. Otherwise, it resolves to "No" and closes by December 31, 2032, at 11:59 PM EST, with the outcome verified by the FDA. Trading is prohibited for individuals with material non-public information or who are employed by Source Agencies.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Before 2033 | $0.38 | $0.69 | 32% |
Market Discussion
The market discussion largely centers on the extended timeframe for the prediction, with several users expressing frustration over the market's distant resolution date in 2033 and questioning its viability as an investment due to perceived low returns. One participant explicitly predicts a "100% no" outcome for a cure being approved, though without providing specific reasons beyond an unfavorable return on investment. No explicit arguments in favor of a "Yes" outcome are presented within the provided comments.
5. Trust Index
Order book is critically thin.
Primary risk· Trade quality
How it adds up
Integrity80% of score84Good
Trade quality20% of score31High Risk
Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.
Trust score74Good
Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index
Trust profile
Integrity4 screens run · 6 don't apply
6. What Key Efficacy Data Has Vertex's VX-880 Shown?
| Insulin Independence (Higher-Dose Part A) | All 6 patients achieved insulin independence [1] |
|---|---|
| Total Insulin Independence | 10 participants achieved insulin independence, 9 within 90 days [1] |
| HbA1c Reduction (Part A) | Reduced from 7.6% (baseline) to 5.0% at 52 weeks for Part A patients [2] |
VX-880 demonstrated significant rates of insulin independence and sustained efficacy. In the ongoing Phase 1/2 study of VX-880, all six patients in the higher-dose Part A group achieved insulin independence following infusion [3]. Three of these Part A patients achieved independence within 90 days of their last infusion [3]. Across the entire trial, a total of 10 participants attained insulin independence, with 9 achieving this within 90 days [1]. Crucially, all participants who achieved insulin independence maintained this status for over 1 year, and three have done so for more than 2 years [1].
Glycemic control significantly improved, marked by substantial HbA1c reductions. Patients in Part A of the study showed a substantial decrease in mean HbA1c levels, falling from 7.6% at baseline to 5.0% at 52 weeks and 5.2% at 78 weeks [2]. For the 10 participants who achieved insulin independence, mean HbA1c levels were reduced from 7.7% at baseline to 5.0% at the 1-year mark [1]. These insulin-independent participants also achieved a mean time-weighted average insulin use of 0.0 units/kg/day [1].
Sources (3)
- 1Zimislecel Enables Insulin Independence in 10 Participants with Type 1 Diabetes | HCPLivehcplive.com
- 2Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | New England Journal of Medicinenejm.org
- 3Vertex Announces Program Updates for Type 1 Diabetes Portfolio | Vertex Pharmaceuticalsinvestors.vrtx.com
7. What New Technologies Are Reversing Type 1 Diabetes?
| Encapsulated Cell Device | Sernova's Cell Pouch™ in efficacy studies [1], a significant breakthrough [2]. |
|---|---|
| Immunomodulation Antibody | Tegoprubart/CFZ533 in Phase 1/2, showing promising insulin independence [3]. |
| Autologous T-reg Cell Therapy | CLBS03 in Phase 2 Safety and Efficacy Study [4]. |
Beyond standard systemic immunosuppression, at least three distinct technological approaches are in advanced T1D trials. These approaches are currently undergoing Phase 2 or Phase 3 human trials with active Investigational New Drug (IND) applications for Type 1 Diabetes (T1D) reversal. The three identified categories are encapsulated cell devices, immunomodulation with specific antibodies for islet transplantation, and autologous T-regulatory cell therapy.
Encapsulated cell devices and autologous cell therapies show promise. One such device is Sernova's Cell Pouch™, designed for clinical islet transplantation, with ongoing studies assessing its safety, tolerability, and efficacy [1]. Efficacy studies typically extend into or lead to later phases, and this work is considered a significant breakthrough in T1D treatment [2]. Another distinct approach is autologous T-regulatory cell therapy, exemplified by CLBS03, which is in a Phase 2 Safety and Efficacy Study for adolescents with recent-onset T1D [4]. This therapy utilizes a patient's own T-regulatory cells to suppress the autoimmune attack on pancreatic beta cells.
Immunomodulation targets specific pathways to prevent rejection. A third technological avenue involves immunomodulation using monoclonal antibodies, specifically against CD40 ligand, such as Tegoprubart/CFZ533. This aims to achieve calcineurin inhibitor-free immunosuppression in T1D patients undergoing islet cell transplantation, thereby reducing the severe side effects associated with broad immunosuppressants [5]. A pilot study is assessing its safety, indicating a Phase 1/2 stage, and has reported promising results for achieving insulin independence [3].
Sources (5)
- 1A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantationctv.veeva.com
- 2Type 1 Diabetes Breakthroughs to Watch in 2026type1strong.org
- 3CLINICAL TRIAL / NCT03513939 - UChicago Medicineuchicagomedicine.org
- 4Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus – CIRMcirm.ca.gov
- 5A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation - Breakthrough T1Dbreakthrought1d.org
8. What is FDA's Stance on Type 1 Diabetes Functional Cure Endpoints?
| FDA 'Functional Cure' for T1D | Not formally defined; no approved 'cure' products [1] |
|---|---|
| Key Endpoint Consideration | Insulin independence, potential primary endpoint in later phase trials [1] |
| Insulin Independence Criteria (HbA1c & Duration) | HbA1c <6.5% or <7% without exogenous insulin for 6 months to 1 year [1] |
The FDA has not formally established specific primary endpoints for T1D 'functional cure'. To date, the FDA has not approved any drug products as a 'cure' for Type 1 Diabetes (T1D) [1]. Despite this, FDA guidance recognizes 'insulin independence' as a significant potential endpoint for investigational T1D therapies, noting it could be considered a primary endpoint in later phase clinical trials if supported by a robust clinical development program [1].
Insulin independence typically involves achieving adequate glycemic control without exogenous insulin. This state is generally understood to include an HbA1c below 6.5% or 7%, maintained for a specified duration, usually ranging from 6 months to 1 year [1]. In addition to glycemic control, evidence of endogenous insulin production, often assessed by stable C-peptide levels, is considered an important component [1]. For example, in trials that led to the approval of the cellular therapy Lantidra, insulin independence was defined as no requirement for exogenous insulin alongside an HbA1c of <6.5% and a fasting C-peptide of >=0.3 ng/mL at 365 days post-transplant [2]. While Lantidra was approved for achieving insulin independence in some patients, it was not described as a 'cure' for T1D [3].
9. What are the safety and durability of allogeneic islet and VX-880 transplantation?
| Allogeneic Islet 5-Year Insulin Independence | 42% for CITR cohort [1] |
|---|---|
| Allogeneic Islet Immunosuppression SAEs | Acute kidney injury and infections [2] |
| VX-880 Max Insulin Independence Duration | 3 years for Patient 1 [3] |
Allogeneic islet transplantation involves manageable immunosuppression risks with varying long-term function. Safety data indicates that adverse events related to immunosuppression are common, though generally mild to moderate, with serious infections being rare [2]. Serious adverse events (SAEs) primarily include acute kidney injury and infections, which are typically manageable with medical treatment [2]. Regarding durability, multi-center studies report 5-year insulin independence rates ranging from 23% to 42%, depending on the recipient type [4]. Overall 5-year graft survival, defined by detectable C-peptide, is observed between 55% and 73% [4]. While long-term function can be achieved, some patients may experience a decline in graft function or a return to exogenous insulin.
VX-880 shows a favorable safety profile and promising long-term durability. The investigational stem cell-derived islet therapy, VX-880, has demonstrated a favorable safety profile in Phase 1/2 clinical trials to date. Serious adverse events specifically attributed to the immunosuppressive regimen have been limited to two cases of acute kidney injury, both of which were mild to moderate and resolved [5]. Durability findings are currently emerging, with several patients maintaining insulin independence and excellent glycemic control beyond the two-year mark. For example, one patient has sustained insulin independence with an HbA1c of 5.3% for three years, indicating prolonged graft function without evidence of graft failure within the observed follow-up period [3].
Sources (5)
- 1Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry - Mayo Clinicmayoclinic.elsevierpure.com
- 2325.8: Efficacy and safety of allogeneic islet transplantation demonstrated by a multicenter clinical trial in Japan.journals.lww.com
- 3Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions | Vertex Pharmaceuticals Newsroomnews.vrtx.com
- 4Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study - Experts@Minnesotaexperts.umn.edu
- 5Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meetingnews.vrtx.com
10. What is Vertex's VX-880 Approval Timeline?
| Most Advanced Candidate | Vertex's Zimislecel (VX-880) [1] |
|---|---|
| Phase 3 Study Status | Planning underway for initiation later in 2024 [1] |
| Earliest Projected Approval | October 2028 [1] |
Vertex's Zimislecel (VX-880) is an advanced Type 1 diabetes candidate. This allogeneic stem cell-derived islet cell therapy completed enrollment in its Phase 1/2 clinical program as of April 2024. Planning for a pivotal Phase 3 study is currently underway and is anticipated to commence later in 2024 [1]. However, official enrollment completion dates and detailed trial protocols for this specific Phase 3 study are not yet publicly available [1].
Projected BLA submission is December 2027 under optimistic assumptions. Assuming the Phase 3 study begins in late 2024, an expedited enrollment period of 1.5 years would hypothetically conclude by June 2026. A subsequent 12-month follow-up for primary endpoints would place primary completion around June 2027. Factoring in an optimistic 6 months for comprehensive data analysis and Biologics License Application (BLA) preparation, the earliest projected BLA submission could be December 2027. If the FDA grants Priority Review, a 10-month review period could lead to a potential approval decision by October 2028.
The projected timeline comfortably meets the buffer requirements for approval. The prediction market deadline is before December 31, 2032, meaning approval would ideally need to occur by December 31, 2031, to account for a 12-month buffer against potential FDA requests for additional data or a Complete Response Letter. The projected October 2028 approval date provides approximately 3 years and 2 months before this buffer point. Even in a scenario where a Complete Response Letter necessitates substantial additional work, estimated at two years, followed by a resubmission and a six-month review, approval could still be achieved by April 2031. This timeline offers more than the requested 12-month buffer prior to the end-of-2032 deadline.
